Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorYale University
About this trial
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.
Disqualifiers
Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.
Trial design
Design model
Single group
Treatments tested in this trial
Implementation Intervention
BehavioralA multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested.
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: Hepatology CliniciansExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Feasibility
Percentage of clinicians enrolled out of all recruited
Time frame
12 monthsSecondary outcomes
1
Acceptability
Percentage of clinicians that attend the educational workshops and utilize implementation tools.
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Yale University
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Source ClinicalTrials.gov